Reduce LDL-C, Apo B, & triglycerides & to increase HDL-C in the treatment of hyperlipidaemias (type IIa or IIb hyperlipoproteinaemias), hypertriglyceridaemia (type IV), & dysbetalipoproteinaemia (type III).
Initially 10-20 mg once daily. Patient who requires large reduction in LDL-C Initially 40 mg daily. May be adjusted at intervals of 4 wk up to a max of 80 mg daily.
Not to be given to patients w/ active liver disease. Assess liver function before starting treatment & subsequently when clinically indicated; additional assessment after 3 mth & before & after dosage increases particularly when high doses are given. Increased risk of myopathy in patients w/ renal impairment. Stop treatment if creatine phosphokinase increases significantly or if myopathy is diagnosed.
Sign Out
